Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents.

Biroccio A, Porru M, Rizzo A, Salvati E, D'Angelo C, Orlandi A, Passeri D, Franceschin M, Stevens MF, Gilson E, Beretta G, Zupi G, Pisano C, Zunino F, Leonetti C.

Clin Cancer Res. 2011 Apr 15;17(8):2227-36. doi: 10.1158/1078-0432.CCR-10-3033. Epub 2011 Feb 25.

2.

PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy.

Salvati E, Scarsella M, Porru M, Rizzo A, Iachettini S, Tentori L, Graziani G, D'Incalci M, Stevens MF, Orlandi A, Passeri D, Gilson E, Zupi G, Leonetti C, Biroccio A.

Oncogene. 2010 Nov 25;29(47):6280-93. doi: 10.1038/onc.2010.344. Epub 2010 Aug 30.

PMID:
20802516
3.

Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90.

Trisciuoglio D, Gabellini C, Desideri M, Ziparo E, Zupi G, Del Bufalo D.

PLoS One. 2010 Jul 27;5(7):e11772. doi: 10.1371/journal.pone.0011772.

4.

In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells.

Ulivi P, Arienti C, Zoli W, Scarsella M, Carloni S, Fabbri F, Tesei A, Chiadini E, Orlandi A, Passeri D, Zupi G, Milandri C, Silvestrini R, Amadori D, Leonetti C.

Curr Cancer Drug Targets. 2010 Sep;10(6):600-10. Review.

PMID:
20491617
5.

Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.

Tesei A, Leonetti C, Zupi G, Scarsella M, Brigliadori G, Ulivi P, Fabbri F, Arienti C, Amadori D, Passardi A, Silvestrini R, Zoli W.

J Cell Mol Med. 2011 Feb;15(2):316-26. doi: 10.1111/j.1582-4934.2009.00993.x.

6.

Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line.

Chevanne M, Zampieri M, Caldini R, Rizzo A, Ciccarone F, Catizone A, D'Angelo C, Guastafierro T, Biroccio A, Reale A, Zupi G, Caiafa P.

J Cell Physiol. 2010 Feb;222(2):401-10. doi: 10.1002/jcp.21964.

PMID:
19890834
7.

Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.

Gabellini C, Trisciuoglio D, Desideri M, Candiloro A, Ragazzoni Y, Orlandi A, Zupi G, Del Bufalo D.

Eur J Cancer. 2009 Sep;45(14):2618-27. doi: 10.1016/j.ejca.2009.07.007. Epub 2009 Aug 13.

PMID:
19683430
8.

Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.

Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, FoĆ  R, Tafuri A, Cognetti F, Anichini A, Zupi G, Milella M.

Neoplasia. 2009 Aug;11(8):720-31.

9.

Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway.

Rizzo A, Salvati E, Porru M, D'Angelo C, Stevens MF, D'Incalci M, Leonetti C, Gilson E, Zupi G, Biroccio A.

Nucleic Acids Res. 2009 Sep;37(16):5353-64. doi: 10.1093/nar/gkp582. Epub 2009 Jul 13.

10.

G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.

Leonetti C, Scarsella M, Riggio G, Rizzo A, Salvati E, D'Incalci M, Staszewsky L, Frapolli R, Stevens MF, Stoppacciaro A, Mottolese M, Antoniani B, Gilson E, Zupi G, Biroccio A.

Clin Cancer Res. 2008 Nov 15;14(22):7284-91. doi: 10.1158/1078-0432.CCR-08-0941.

11.

Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma.

Gabellini C, Castellini L, Trisciuoglio D, Kracht M, Zupi G, Del Bufalo D.

J Neurochem. 2008 Nov;107(3):871-82. doi: 10.1111/j.1471-4159.2008.05661.x. Epub 2008 Sep 11.

12.

CCCTC-binding factor activates PARP-1 affecting DNA methylation machinery.

Guastafierro T, Cecchinelli B, Zampieri M, Reale A, Riggio G, Sthandier O, Zupi G, Calabrese L, Caiafa P.

J Biol Chem. 2008 Aug 8;283(32):21873-80. doi: 10.1074/jbc.M801170200. Epub 2008 Jun 5.

13.

Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect.

Salvati E, Leonetti C, Rizzo A, Scarsella M, Mottolese M, Galati R, Sperduti I, Stevens MF, D'Incalci M, Blasco M, Chiorino G, Bauwens S, Horard B, Gilson E, Stoppacciaro A, Zupi G, Biroccio A.

J Clin Invest. 2007 Nov;117(11):3236-47.

14.

Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression.

Giorgini S, Trisciuoglio D, Gabellini C, Desideri M, Castellini L, Colarossi C, Zangemeister-Wittke U, Zupi G, Del Bufalo D.

Mol Cancer Res. 2007 Aug;5(8):761-71.

15.

Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.

Leonetti C, Biroccio A, D'Angelo C, Semple SC, Scarsella M, Zupi G.

Prostate. 2007 Sep 15;67(13):1475-85.

PMID:
17654511
16.

Gamma-glutamylcysteine synthetase mediates the c-Myc-dependent response to antineoplastic agents in melanoma cells.

Benassi B, Zupi G, Biroccio A.

Mol Pharmacol. 2007 Oct;72(4):1015-23. Epub 2007 Jul 12.

17.
18.

R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.

Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A.

J Cell Physiol. 2007 May;211(2):533-43.

PMID:
17192846
19.

Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers.

Hugo H, Cures A, Suraweera N, Drabsch Y, Purcell D, Mantamadiotis T, Phillips W, Dobrovic A, Zupi G, Gonda TJ, Iacopetta B, Ramsay RG.

Genes Chromosomes Cancer. 2006 Dec;45(12):1143-54.

PMID:
16977606
20.

Involvement of RB gene family in tumor angiogenesis.

Gabellini C, Del Bufalo D, Zupi G.

Oncogene. 2006 Aug 28;25(38):5326-32. Review.

PMID:
16936754
21.

TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells.

Biroccio A, Rizzo A, Elli R, Koering CE, Belleville A, Benassi B, Leonetti C, Stevens MF, D'Incalci M, Zupi G, Gilson E.

Eur J Cancer. 2006 Aug;42(12):1881-8. Epub 2006 Jun 5.

PMID:
16750909
22.

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.

Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M.

Cancer Res. 2006 Jun 1;66(11):5549-54.

23.

Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts.

Leonetti C, Scarsella M, Zupi G, Zoli W, Amadori D, Medri L, Fabbri F, Rosetti M, Ulivi P, Cecconetto L, Bolla M, Tesei A.

Mol Cancer Ther. 2006 Apr;5(4):919-26.

24.

c-Myc phosphorylation is required for cellular response to oxidative stress.

Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M, Zupi G, Biroccio A.

Mol Cell. 2006 Feb 17;21(4):509-19.

25.

Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells.

Zupi G, Scarsella M, D'Angelo C, Biroccio A, Paoletti G, Lopez M, Leonetti C.

Cancer Biol Ther. 2005 Aug;4(8):866-71.

PMID:
16210917
26.

Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells.

Trisciuoglio D, Iervolino A, Zupi G, Del Bufalo D.

Mol Biol Cell. 2005 Sep;16(9):4153-62. Epub 2005 Jun 29.

27.

Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth.

Trisciuoglio D, Desideri M, Ciuffreda L, Mottolese M, Ribatti D, Vacca A, Del Rosso M, Marcocci L, Zupi G, Del Bufalo D.

J Cell Physiol. 2005 Dec;205(3):414-21.

PMID:
15920759
28.

Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function.

Del Bufalo D, Rizzo A, Trisciuoglio D, Cardinali G, Torrisi MR, Zangemeister-Wittke U, Zupi G, Biroccio A.

Cell Death Differ. 2005 Nov;12(11):1429-38.

29.

Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.

De Cesare M, Perego P, Righetti SC, Pratesi G, Carenini N, Rivoltini L, Zupi G, Del Bufalo D, Balsari A, Zunino F.

Eur J Cancer. 2005 May;41(8):1213-22.

PMID:
15911246
30.

Are we close to the clinical development of novel drugs targeting telomeres and telomerase?

D'Incalci M, Zupi G.

Eur J Cancer. 2005 May;41(7):970. No abstract available.

PMID:
15862744
31.
32.

In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines.

Tesei A, Ulivi P, Fabbri F, Rosetti M, Leonetti C, Scarsella M, Zupi G, Amadori D, Bolla M, Zoli W.

J Transl Med. 2005 Feb 3;3(1):7.

33.

Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab.

Biroccio A, D'Angelo C, Jansen B, Gleave ME, Zupi G.

J Cell Physiol. 2005 Aug;204(2):463-9.

PMID:
15685647
34.

pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol.

Tonini T, Gabellini C, Bagella L, D'Andrilli G, Masciullo V, Romano G, Scambia G, Zupi G, Giordano A.

Clin Cancer Res. 2004 Dec 1;10(23):8085-93.

35.

Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.

Milella M, Trisciuoglio D, Bruno T, Ciuffreda L, Mottolese M, Cianciulli A, Cognetti F, Zangemeister-Wittke U, Del Bufalo D, Zupi G.

Clin Cancer Res. 2004 Nov 15;10(22):7747-56.

36.

Lonidamine causes inhibition of angiogenesis-related endothelial cell functions.

Del Bufalo D, Trisciuoglio D, Scarsella M, D'Amati G, Candiloro A, Iervolino A, Leonetti C, Zupi G.

Neoplasia. 2004 Sep-Oct;6(5):513-22.

37.

45th annual meeting of the Italian Cancer Society. Bergamo, 9-12 November 2003.

Giavazzi R, Aglietta M, Astolfi A, Falanga A, Fusco A, Labianca R, Lollini PL, Lombardo C, Natali PG, Pierotti MA, Presta M, Santoro M, Taraboletti G, Zupi G, Vecchio G.

Tumori. 2004 May-Jun;90(3):356-62.

PMID:
15315322
38.

Biological activity of the G-quadruplex ligand RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) is associated with telomere capping alteration.

Leonetti C, Amodei S, D'Angelo C, Rizzo A, Benassi B, Antonelli A, Elli R, Stevens MF, D'Incalci M, Zupi G, Biroccio A.

Mol Pharmacol. 2004 Nov;66(5):1138-46. Epub 2004 Aug 10.

39.

Ras inhibition amplifies cisplatin sensitivity of human glioblastoma.

Messina S, Leonetti C, De Gregorio G, Affatigato V, Ragona G, Frati L, Zupi G, Santoni A, Porcellini A.

Biochem Biophys Res Commun. 2004 Jul 23;320(2):493-500.

PMID:
15219856
40.

Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents.

Biroccio A, Benassi B, Fiorentino F, Zupi G.

Neoplasia. 2004 May-Jun;6(3):195-206.

41.

In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors.

Leonetti C, Scarsella M, Semple SC, Molinari A, D'Angelo C, Stoppacciaro A, Biroccio A, Zupi G.

Int J Cancer. 2004 Jul 10;110(5):767-74.

42.

Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice.

D'Alessio S, Margheri F, Pucci M, Del Rosso A, Monia BP, Bologna M, Leonetti C, Scarsella M, Zupi G, Fibbi G, Del Rosso M.

Int J Cancer. 2004 May 20;110(1):125-33.

43.

bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity.

Trisciuoglio D, Iervolino A, Candiloro A, Fibbi G, Fanciulli M, Zangemeister-Wittke U, Zupi G, Del Bufalo D.

J Biol Chem. 2004 Feb 20;279(8):6737-45. Epub 2003 Dec 1.

44.

Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity.

Del Bufalo D, Trisciuoglio D, Scarsella M, Zangemeister-Wittke U, Zupi G.

Oncogene. 2003 Nov 20;22(52):8441-7.

PMID:
14627985
45.

Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.

Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, Xu W, Kalish V, Zupi G, Zhang J, Graziani G.

Clin Cancer Res. 2003 Nov 1;9(14):5370-9.

46.

The future of antisense therapy: combination with anticancer treatments.

Biroccio A, Leonetti C, Zupi G.

Oncogene. 2003 Sep 29;22(42):6579-88. Review.

PMID:
14528283
47.

Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1.

Gabellini C, Antonelli A, Petrinelli P, Biroccio A, Marcucci L, Nigro G, Russo G, Zupi G, Elli R.

Br J Cancer. 2003 Sep 15;89(6):1091-5.

48.

Inhibition of c-Myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis.

Biroccio A, Amodei S, Antonelli A, Benassi B, Zupi G.

J Biol Chem. 2003 Sep 12;278(37):35693-701. Epub 2003 Jun 24.

49.

Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells.

Biroccio A, Gabellini C, Amodei S, Benassi B, Del Bufalo D, Elli R, Antonelli A, D'Incalci M, Zupi G.

Mol Pharmacol. 2003 Mar;63(3):632-8.

50.

Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy.

Leonetti C, Biroccio A, Gabellini C, Scarsella M, Maresca V, Flori E, Bove L, Pace A, Stoppacciaro A, Zupi G, Cognetti F, Picardo M.

Int J Cancer. 2003 Mar 20;104(2):243-50.

Supplemental Content

Support Center